深圳惠泰医疗器械股份有限公司 独立董事关于第二届董事会第八次会议相关议案的 独立意见 我们作为深圳惠泰医疗器械股份有限公司(以下简称"公司")的独立董事, 根据相关法律、法规、规范性文件以及《深圳惠泰医疗器械股份有限公司章程》 (以下简称"《公司章程》")和《深圳惠泰医疗器械股份有限公司独立董事工 作制度》的规定,基于独立判断的立场,在仔细审阅了第二届董事会第八次会议 的相关文件后,经审慎分析发表如下独立意见: 一、《关于公司<2023 年半年度募集资金存放与实际使用情况的专项报告> 的议案》 经审阅,我们认为公司董事会编制的《深圳惠泰医疗器械股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告》所载内容真实、准确、完整 地反映了公司的实际情况,不存在任何虚假记载、误导性陈述、重大遗漏。公司 按照相关法律法规、《公司章程》《深圳惠泰医疗器械股份有限公司募集资金管 理制度》的有关要求建立了募集资金专户进行存储和专项使用,不存在变相改变 募集资金用途、违规存放与使用募集资金的情形,也不存在损害公司及股东、尤 其是中小股东利益的情形。 综上,我们一致同意该议案。 (以下无正文) - 1 - (本页无 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2023-035 投资者可于 2023 年 8 月 23 日（星期三）至 8 月 29 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aptmed.com进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 深圳惠泰医疗器械股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 30 日（星期三）上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.ss einfo.com/） 会议召开方式：上证路演中心网络互动 深圳惠泰医疗器械股份有限公司（以下简称"公司"）将于 2023 年 8 月 25 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 8 月 30 日（星期三）上午 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 349,712,760.42, representing a year-on-year increase of 31.71%[4] - Net profit attributable to shareholders was RMB 102,686,545.40, reflecting a growth of 53.71% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was RMB 90,064,379.49, up by 49.08% year-on-year[4] - Basic earnings per share for the period were RMB 1.54, an increase of 54.00% compared to the previous year[4] - The company reported a gross profit margin of approximately 29.1% for Q1 2023, compared to 24.8% in Q1 2022[17] - The total comprehensive income attributable to the parent company's owners for Q1 2023 was ¥102,497,749.73, a significant increase of 53.5% compared to ¥66,796,970.25 in Q1 2022[19] Cash Flow - The net cash flow from operating activities reached RMB 116,347,052.18, marking a significant increase of 74.73%[4] - Cash inflow from operating activities totaled ¥424,986,539.90 in Q1 2023, up from ¥315,380,775.19 in Q1 2022, representing a 34.7% increase[20] - Cash outflow from operating activities increased to ¥308,639,487.72 in Q1 2023, compared to ¥248,793,254.26 in Q1 2022, a rise of 24%[22] - The company reported a net increase in cash and cash equivalents of ¥256,309,734.91 for Q1 2023, compared to ¥105,041,796.89 in Q1 2022, reflecting a 143% increase[22] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,382,598,153.66, a 7.04% increase from the end of the previous year[5] - The company's total assets amounted to RMB 2,382,598,153.66, an increase from RMB 2,225,978,346.27 as of December 31, 2022, reflecting a growth of approximately 7.06%[13] - The total current assets increased to RMB 1,690,030,123.98 from RMB 1,557,457,712.49, representing a growth of about 8.49%[14] - The total liabilities as of March 31, 2023, were ¥487,206,301.68, compared to ¥434,912,807.26 at the end of 2022, indicating a 12.0% rise[16] - The company's total liabilities increased, with accounts payable rising to RMB 41,849,945.07 from RMB 41,220,788.18, an increase of 1.53%[14] Research and Development - R&D investment totaled RMB 52,606,928.37, which accounted for 15.04% of operating revenue, a decrease of 1.71 percentage points[5] - Research and development expenses in Q1 2023 amounted to ¥52,606,928.37, an increase of 18.3% from ¥44,482,715.95 in Q1 2022[17] Market and Growth - The increase in sales scale and improved product profitability were key drivers for the significant profit growth[8] - The company continues to expand its market presence, particularly in overseas markets and OEM business, contributing to sustained revenue growth[8] - The company has not disclosed any significant new product developments or market expansion strategies in this quarter[12]

深圳惠泰医疗器械股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688617 证券简称：惠泰医疗 公告编号：2023-015 重要内容提示： 会议召开时间：2023 年 4 月 19 日（星期三）上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 12 日（星期三）至 4 月 18 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aptmed.com进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）已于 2023 年 4 月 7 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 ...

Financial Performance - The company's total revenue for 2022 was RMB 828.69 million, representing a 46.74% increase compared to RMB 479.44 million in 2021[23]. - Net profit attributable to shareholders for 2022 was RMB 207.92 million, a 72.19% increase from RMB 110.78 million in 2021[23]. - The net profit after deducting non-recurring gains and losses was RMB 167.58 million, up 92.02% from RMB 97.74 million in 2021[23]. - The net cash flow from operating activities increased by 102.58% to RMB 181.39 million, compared to RMB 148.24 million in 2021[23]. - Basic earnings per share for 2022 were RMB 5.38, a 68.65% increase from RMB 3.19 in 2021[24]. - Operating profit reached CNY 396,988,398.43, up 78.42% compared to the previous year[88]. - Net profit attributable to shareholders was CNY 358,019,712.33, reflecting a growth of 72.19% year-on-year[88]. - The gross margin for the main business was 71.28%, an increase of 1.77 percentage points from the previous year[92]. - The company achieved operating revenue of CNY 1,216,017,969.28, a year-on-year increase of 46.74%[88]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 16.50 per 10 shares, totaling approximately RMB 109.49 million, which represents 47.34% of the net profit attributable to shareholders for the year 2022[5]. - The total amount of dividends (including tax) is CNY 169,481,513.55, representing 47.34% of the net profit attributable to ordinary shareholders in the consolidated financial statements[171]. Research and Development - The company's R&D investment as a percentage of revenue was 14.38%, down from 16.28% in 2021[24]. - R&D investment over the past three years was 71.9 million, 134.9 million, and 174.9 million CNY, representing 15.00%, 16.28%, and 14.38% of revenue respectively[34]. - The company reported a total R&D investment of ¥174,876,346.09 in the current year, representing a 29.66% increase from ¥134,876,802.74 in the previous year[61]. - The company filed 50 new patent applications during the reporting period, with 15 patents granted, bringing the cumulative total to 297 applications and 140 granted[60]. - The company has invested a total of ¥30,888.36 million in R&D projects, with ¥8,477.93 million invested in the current period and a cumulative investment of ¥21,815.48 million[67]. Market Expansion and Strategy - The company plans to continue expanding its market presence and enhancing its product lines, particularly in overseas markets and OEM business[23]. - The company expanded its domestic market presence by adding over 300 new hospitals for electrophysiology products, increasing its coverage to over 800 hospitals[32]. - International business grew by 72.05% year-on-year, with Eastern Europe, CIS, and Western Europe seeing growth exceeding 100%[34]. - The company plans to continue investing in new product and technology development while enhancing market expansion efforts[32]. - The company aims to enhance its product line in electrophysiology and vascular intervention, focusing on innovation and market expansion to maintain a competitive edge[119]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures for providing guarantees[8]. - The company has not experienced any situation where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the annual report[8]. - The company has not reported any special arrangements for corporate governance[6]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute substantive commitments to investors[7]. Risk Management - The company has detailed various risks and countermeasures in the report, which can be found in the "Management Discussion and Analysis" section[3]. - The company is facing significant risks related to new product development failures and registration challenges in the interventional medical device industry, which has high R&D difficulty and barriers[79]. - The company is exposed to macroeconomic risks, including currency fluctuations and depreciation of local currencies, which can impact purchasing power and overall market conditions[86]. Employee and Talent Development - The company emphasizes talent development and has built a high-quality team across various disciplines to support its strategic goals[35]. - The company has established a competitive compensation system to attract and retain talent, including performance bonuses and stock incentives[165]. - The company plans to invest in talent development and management culture to support its rapid growth objectives in 2023[127]. - The company is committed to continuous employee training and career development opportunities, fostering a supportive work environment[199]. Environmental and Social Responsibility - The company invested approximately 2.3 million RMB in environmental protection measures during the reporting period[183]. - The company has implemented measures to reduce carbon emissions, although specific tonnage reductions were not disclosed[189]. - The company donated a total of 2.77 million RMB to various charitable foundations and projects during the reporting period[193]. - The company actively supports rural revitalization through educational assistance and infrastructure development, aligning with national policies[197]. Internal Control and Compliance - The internal control system of the company operated effectively during the reporting period, with no significant control deficiencies identified[179]. - The company received a standard unqualified opinion on its internal control audit for the 2022 financial report, confirming the effectiveness of its internal controls[181]. - The company is committed to strict compliance with laws and regulations to optimize its governance structure and decision-making processes[128].

Financial Performance - The company's operating revenue for Q3 2022 was ¥331,669,714.11, representing a year-on-year increase of 58.96%[4] - The net profit attributable to shareholders for Q3 2022 was ¥101,704,287.93, reflecting a significant increase of 115.59% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥92,171,303.60, up 105.31% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥1.53, an increase of 115.49% compared to the same period last year[5] - Total revenue for the first three quarters of 2022 reached ¥887,326,586.93, a significant increase of 49.6% compared to ¥593,394,901.72 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was ¥247,647,452.87, representing a 59.3% increase from ¥155,423,196.22 in the same period of 2021[22] - The net profit attributable to the parent company for the first three quarters of 2022 was approximately ¥260.58 million, an increase of 60.8% compared to ¥162.03 million in the same period of 2021[23] - Basic earnings per share for the first three quarters of 2022 were ¥3.91, up from ¥2.50 in the same period of 2021, reflecting a growth of 56%[24] - Total comprehensive income for the first three quarters of 2022 reached approximately ¥251.54 million, compared to ¥155.42 million in the same period of 2021, marking an increase of 61.8%[23] Research and Development - The total R&D investment for Q3 2022 was ¥45,951,832.90, which is a 49.50% increase year-on-year[5] - Research and development expenses for the first three quarters of 2022 were ¥134,322,322.41, a significant increase of 65.8% from ¥81,026,091.54 in the same period of 2021[22] - The company has increased its investment in new product and technology development, which is expected to drive future growth[9] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥279,573,710.23, reflecting a significant increase of 209.24%[5] - Cash inflow from operating activities for the first three quarters of 2022 was approximately ¥1.02 billion, compared to ¥702.61 million in the same period of 2021, representing an increase of 45%[25] - The net cash flow from operating activities for the first three quarters of 2022 was approximately ¥279.57 million, significantly higher than ¥90.41 million in the same period of 2021, indicating a growth of 209%[26] - The company's cash and cash equivalents as of September 30, 2022, amounted to ¥389,175,392.30, an increase from ¥309,660,762.50 as of December 31, 2021[17] - The ending balance of cash and cash equivalents as of September 30, 2022, was approximately ¥389.18 million, compared to ¥124.67 million at the end of the same period in 2021, reflecting a significant increase of 211%[27] Shareholder Information - Total number of common shareholders at the end of the reporting period was 4,506[11] - The largest shareholder, Cheng Zhenghui, holds 16,685,027 shares, representing 25.03% of total shares[11] - There were no significant changes in the status of shares held by major shareholders, with no pledges or freezes reported[11] - The total number of shareholders with voting rights restored for preferred shares was not applicable[11] Liabilities and Equity - Total liabilities increased to ¥447,670,542.76 as of September 30, 2022, compared to ¥222,016,219.03 at the end of 2021, marking a substantial rise of 101.5%[19] - The company reported a total equity of ¥1,687,876,108.45 as of September 30, 2022, down from ¥1,791,065,324.70 at the end of 2021, indicating a decrease of 5.8%[19] Future Outlook - The company plans to continue enhancing product performance and expanding market reach, contributing to revenue growth[9] - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[22] - The company has not disclosed any significant new strategies or product developments in the current reporting period[15]

Financial Performance - The company reported a total revenue of RMB 200 million for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company's operating revenue for the first half of 2022 was ¥555,656,872.82, representing a 44.42% increase compared to ¥384,740,292.01 in the same period last year[17]. - Net profit attributable to shareholders was ¥158,872,593.10, up 38.33% from ¥114,853,593.06 year-on-year[19]. - The net cash flow from operating activities increased by 61.50%, reaching ¥179,897,006.36, driven by higher sales revenue[19]. - Basic earnings per share rose to ¥2.38, a 32.22% increase from ¥1.80 in the previous year[18]. - The company's total assets at the end of the reporting period were ¥2,190,538,688.24, an 8.82% increase from ¥2,013,081,543.73 at the end of the previous year[17]. - The company's net profit after deducting non-recurring gains and losses was ¥140,836,218.34, reflecting a 39.96% increase from ¥100,624,804.79 year-on-year[17]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization measures[1]. Research and Development - Research and development expenses increased by 30% to RMB 50 million, focusing on innovative medical device technologies[1]. - The R&D investment as a percentage of operating revenue was 15.90%, up from 13.07% in the previous year, indicating a focus on innovation[18]. - The company reported a total R&D investment of ¥88,370,489.51, representing a 75.72% increase compared to the previous year[46]. - The company holds a total of 102 authorized patents, including 100 domestic patents and 2 overseas patents, as of June 30, 2022[44]. - The company has developed a controllable bending catheter that improves safety and reduces surgery time, allowing access to both left and right coronary arteries[41]. - The company has established a technology innovation system with R&D centers in Shenzhen, Hunan, and Shanghai, focusing on electrophysiological consumables and devices[54]. Market Expansion and Strategy - The company expects a revenue growth of 20% for the full year 2022, driven by new product launches and market expansion strategies[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - A strategic acquisition of a local competitor is under consideration to enhance product offerings and distribution channels[1]. - The company has established partnerships with three major hospitals to enhance product visibility and user adoption[1]. - The company is actively pursuing international market access, with plans to register 6 to 9 new products in the Eurasian region by the end of 2022[64]. Product Development - The company has launched two new products in the coronary intervention segment, projected to contribute an additional RMB 30 million in revenue by year-end[1]. - The company has launched the first domestic registered product in the category of adjustable valve catheter sheaths, enhancing its product offerings in peripheral access devices[27]. - The company has developed unique products such as the thin-walled sheath and the adjustable valve catheter sheath, which are the first of their kind in the domestic market[55]. - The company has achieved international leadership in hybrid metal wire connection technology, enhancing torque transmission in guidewires[40]. - The company’s innovative design for the coronary sinus mapping electrode catheter significantly reduces placement time and has received positive market feedback[40]. Financial Risks and Challenges - The management highlighted potential risks related to regulatory changes in the medical device industry, which could impact future growth[1]. - The company faces risks related to new product development failures and registration challenges, which could impact revenue and profitability[68]. - The company operates in a highly competitive market where foreign brands hold over 80% market share, posing a risk to its competitive advantage[71]. - The company is subject to stringent regulatory oversight regarding product quality, with potential legal liabilities if significant quality issues arise[75]. Environmental and Social Responsibility - The company implemented measures to reduce carbon emissions, achieving a reduction through source control, process control, and terminal tracking[103]. - The company donated 450,000 yuan for rural infrastructure projects, including water conservancy construction in May 2022[105]. - The company encourages employees to use public transport, electric vehicles, or bicycles to reduce carbon emissions[104]. - The company strictly complies with environmental laws and regulations, ensuring stable compliance with emission standards[102]. - The company has established a comprehensive environmental management system to enhance environmental risk management[102]. Shareholder and Governance - The company has committed to not transferring or entrusting the management of shares held before the IPO for 36 months from the date of listing[111]. - The company will ensure that any share reduction within two years after the lock-up period does not occur below the issue price[113]. - The company has outlined responsibilities for shareholders in case of violations of the lock-up commitments that cause losses to the company or investors[116]. - The company has established a voluntary lock-up commitment for core technical personnel for 12 months post-listing and 6 months after leaving the company[116]. - The company will publicly disclose reasons for any failure to fulfill commitments and apologize to shareholders if it does not meet its commitments[144].